A new Alzheimer's drug has been described as a potential "wonder drug" after early trial results reportedly showed it could delay the progression of the disease by up to three years, with signs suggesting around 90% of brain damage markers seen in patients diminished during testing. If confirmed by further research, this would represent a significant step forward in treating a condition that currently has very limited options for slowing cognitive decline once symptoms begin.

The article's full details on the trial's methodology, patient numbers and the specific drug involved were not available in the source text supplied, so these figures should be treated as preliminary and unverified pending peer-reviewed publication and larger-scale studies. As with other recent Alzheimer's drug developments, experts would typically caution that early trial results need to be replicated in larger, controlled studies before any treatment could become widely available.